Characteristic | Value |
Chemotherapy (prior to study inclusion) | |
Total | 23 (100%) |
Capecitabine | 22 (96%) |
Oxaliplatin | 21 (91%) |
Bevacizumab | 14 (61%) |
Irinotecan | 11 (48%) |
5-fluorouracil | 6 (26%) |
Leucovorin | 5 (22%) |
Panitumumab | 4 (17%) |
Cetuximab | 1 (4%) |
Dabrafenib | 1 (4%) |
Tegafur-uracil | 1 (4%) |
Targeted part of liver | |
Whole liver | 36 (95%) |
Right lobe | 2 (5%) |
Left lobe | 0 (0%) |
Treatment sessions | |
1 | 36 (95%) |
2 | 2 (5%) |
Specific activity (MBq/mg)* | 11.26 (4.95–21.34) |
Infused activity (MBq)* | 6,412 (2,213–13,189) |
Administration of treatment dose† | 96% (41%–99%) |
Adequate administration of activity (>90%)‡ | 26/37 (70%) |
Absorbed liver dose (Gy) | 51 (26–69) |
Predicted lung shunt (99mTc-MAA) | 3.2% (0.01%–19.3%) |
Actual lung shunt (166Ho) | 0.02% (0%–0.7%) |
↵* All injections combined (including scout dose), at respective time of injection.
↵† Percentage of prepared.
↵‡ In other patients, stasis occurred or infusion was stopped because of pain.
Qualitative data are expressed as numbers followed by percentages in parentheses; continuous data are expressed as median followed by range in parentheses.